Michael Thase, MD
Psychiatry · Philadelphia, PANPI 1982670279
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.5%. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $1471.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$89K
- Otsuka Pharmaceutical Co., Ltd.$70K
- Boehringer Ingelheim International GmbH$27K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$23K
- Janssen Research & Development, LLC$22K
- Merck$22K
- plus $142K from 18 others
Across 197 payments — averaging $8986.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.2M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$317K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115K
- Merck$80K
- Acadia Pharmaceuticals Inc$64K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- plus $3K from 1 others
What the payments were for
- Consulting fees$176,06944%
- Speaking & faculty fees$147,00937%
- Travel & lodging$67,40117%
- Food & beverage$5,2301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 28 | $89,119 |
| Otsuka Pharmaceutical Co., Ltd. | 46 | $69,972 |
| Boehringer Ingelheim International GmbH | 10 | $26,749 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $23,227 |
| Janssen Research & Development, LLC | 16 | $22,439 |
| Merck | 28 | $22,029 |
| Johnson & Johnson | 16 | $21,390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $21,290 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $15,052 |
| Janssen Scientific Affairs, LLC | 13 | $13,614 |
| Sage Therapeutics, LLC | 13 | $11,837 |
| E.r. Squibb & Sons, L.L.C. | 5 | $11,275 |
| Mylan Inc. | 3 | $10,405 |
| Alkermes, Inc. | 4 | $7,655 |
| Jazz Pharmaceuticals Inc. | 11 | $6,459 |
| AbbVie(2 entities) | 5 | $5,169 |
| Eli Lilly | 3 | $4,713 |
| Pfizer | 1 | $4,533 |
| Luye Pharma (USA) Ltd. | 4 | $3,655 |
| Boehringer Ingelheim | 6 | $2,529 |
| Janssen Global Services, LLC | 1 | $2,500 |
| Otsuka America Pharmaceutical, Inc. | 1 | $44 |
| Upjohn US 1 LLC | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$149,870
- SPRAVATO$25,688
- TRINTELLIX$20,881
- BRINTELLIX$17,158
- CAPLYTA$14,674
- ESCITALOPRAM$11,868
- PRISTIQ$4,533
- SUNOSI$3,551
- Rykindo$3,500
- MK-1942$2,250
- QULIPTA$2,025
- VRAYLAR$575
How this compares
$395,710 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Perphenazine | 23 | $1,737 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,657 |
| Bupropion XlBupropion Hcl | 12 | $901 |
| Lithium Carbonate ErLithium Carbonate | 22 | $775 |
| Clonazepam | 85 | $744 |
| Duloxetine Hcl | 16 | $535 |
| Quetiapine Fumarate | 25 | $527 |
| Methylphenidate Hcl | 21 | $314 |
| Lamotrigine | 11 | $213 |
| Diazepam | 23 | $53 |
| Atorvastatin Calcium | 13 | $42 |
| Trazodone Hcl | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mylan Inc.Atorvastatin Calcium | $10,405 | $4213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.